Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Activist investors tend to rely on an element of surprise to catch their target company off guard: quietly building up a stake and swooping in with a slide deck full of strategic changes at just the ...

Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

This is an audio transcript of the Behind the Money podcast episode: ‘An activist tried to take on Pfizer. Then things got ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

With Pfizer’s stock down sharply, an activist investor is pushing for CEO Albert Bourla to improve performance.